hotspot -WSS

hotspot

author：leisure time 2025-09-28 22:53:32 - browse：7513

Verve Therapeutics CEO Sekar Kathiresan Verve

SAN FRANCISCO — The promise of genome editing has given rise to potentially curative medicines for rare, life-threatening diseases that generally affect small numbers of patients. But since Verve Therapeutics was founded in 2018, it’s had a wider aperture: using the molecular tools of genome editing to go after the most common cause of death in the world.

The plan, according to Verve CEO Sekar Kathiresan, is to edit out heart attacks for the millions of people at risk for severe cardiovascular disease. It’s a goal that’s more than a little audacious. There’s just one approved genome editing medicine, a treatment for sickle cell disease, and it only passed Food and Drug Administration review last month. Base editing, the CRISPR successor Verve uses to conduct its molecular surgery, is only a few years old.

“When we started, there were so many things that we were kind of going against the grain on,” Kathiresan told STAT at the J.P. Morgan Healthcare Conference in San Francisco this week. “In 2018, it was all about platforms, not about specific diseases and products, or taking this kind of idea for a large indication as opposed to cancer or rare disease. But we’ve always been motivated by a deep conviction in one simple research insight, which is that if your blood cholesterol is really low, lifelong, it is very hard to get a heart attack.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Why health workers in Gaza are injured or die at high rates

Wikipedia

WSS

Sudafed saga points to U.S. issues with evaluating older drugs

Kaiser Permanente unions announce official strike date

Sudafed saga points to U.S. issues with evaluating older drugs

UnitedHealth’s board chair also owns a personal investment firm

STAT Readout Newsletter: Today's biggest biotech updates

FDA seeks to regulate lab

leisure time

hotspot

leisure time

The cancer drug shortage isn’t new — and neither are the solutions

Beam Therapeutics to lay off 20% of its staff, re

Duchenne breakthrough therapy leaves behind pioneering families

Sudafed saga points to U.S. issues with evaluating older drugs

Psychedelics group wrestles with new pharma identity

HHS leader on health, climate change and biopharma emissions

FDA approval of Sarepta Duchenne genetic therapy gives me hope

HHS leader on health, climate change and biopharma emissions

Drug repurposing or repositioning? The language matters

Senator probes 340B programs at Cleveland Clinic, Bon Secours

hotspot

FDA struggles to regulate food additives, sometimes for decades

Intercept Pharmaceuticals sells itself for less than $1 billion

STAT Summit: Biotech founders on deal

NIH confirmation hearing shows politicization of research

Will Ozempic

How climate

focus

Wikipedia

knowledge

hotspot